Clinical and epidemiological features of motor neuron disease in south-western Greece

Polychronopoulos, Panagiotis; Papapetropoulos, Spiridon; Ellul, John; Andriopoulos, Ioannis; Katsoulas, George; Salakou, Stavroula; Chroni, Elisabeth

doi:10.1111/j.1600-0404.2004.00362.x

Cited by 45 publications

(40 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Alternatively, it may reflect improved detection methods, increased reporting rates, better access to medical care (with increased diagnostic rates) and refinement of epidemiological methods to study ALS 17 . Our findings suggest that, similarly to what has been reported by others, ALS is rare in the Brazilian population, although being the most prevalent of the motor neuron disorders 13,14 . Regarding patient-related characteristics, we found no differences in mortality by gender.…”

Section: Discussionsupporting

confidence: 91%

“…Several studies have investigated the prevalence of ALS, and better characterized samples have come from the in Europe and United States 13,14 . In Brazil few studies focused on the incidence of ALS, as well as on mortality rates associated with the disease, making it difficult to establish the magnitude and risk factors of ALS in our Country, justifying this investigation.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Mortality rates due to amyotrophic lateral sclerosis in São Paulo City from 2002 to 2006

Matos

Conde

Fávero

et al. 2011

Arq. Neuro-Psiquiatr.

View full text Add to dashboard Cite

OBJECTIVE: To describe the mortality rates of amyotrophic lateral sclerosis (ALS) in the city of São Paulo as a function of demographics, year, and region. METHOD: This was a retrospective descriptive study. Information was obtained from death certificates registered at the Program for the Improvement of Mortality Information, Municipal Health Department (PRO-AIM/SMS), coded as G12.2 according to International Classification of Diseases (ICD-10), from 2002 to 2006. RESULTS: Over the studied time, were found 326 deaths (51.6% women, overall mean age of 64.1 years). Highest deaths percentages happened in those from 60 to 69 and 70 to 79 years and in white individuals. ALS mortality rates ranged 0.44/100,000 in 2002 and 0.76/100,000 in 2006. No significant changes overtime in administrative districts were found. CONCLUSION: ALS mortality rates in São Paulo were lower in comparison to other countries, however any risk factor in our environment, lifestyle or genetic characteristics were found.

show abstract

Section: Discussionsupporting

confidence: 91%

Section: Discussionmentioning

confidence: 99%

Mortality rates due to amyotrophic lateral sclerosis in São Paulo City from 2002 to 2006

Matos

Conde

Fávero

et al. 2011

Arq. Neuro-Psiquiatr.

View full text Add to dashboard Cite

show abstract

“…On the contrary, the present study found 127 men (55%) and 104 women (45%) with ALS. This predominance of males agrees with the studies by Lee et al 6 , McCombe and Henderson 3 , Zoccolella et al 15 , Argyriou et al 1 , Palermo et al 2 and Logroscino et al 4,5,16 . Some studies reported that this male preponderance is due to heavy industries and agricultural jobs 1,3,6,7 .…”

Section: Epidemiological Characteristicssupporting

confidence: 82%

Epidemiological and clinical factors impact on the benefit of riluzole in the survival rates of patients with ALS

Fávero

Voos

Castro

et al. 2017

Arq. Neuro-Psiquiatr.

View full text Add to dashboard Cite

Objective To investigate the impact of epidemiological and clinical factors on the benefit of riluzole in patients with amyotrophic lateral sclerosis (ALS). Methods The survival rate of 578 patients with ALS (1999-2011) was analyzed by descriptive statistics and Kaplan-Meier curves. Considering the median of the sample survival time (19 months), patients were divided in two groups: below (B19) and above the median (A19). Kaplan-Meier curves compared the survival rates of patients treated with riluzole and with patients who did not take the medication. Results Riluzole increased the survival rates of patients with lower limb onset who were diagnosed after the first appointment in B19. Patients with bulbar onset and diagnosed on the first, or after the first appointment showed higher survival rates in A19. Males lived longer than females in both groups. Conclusion Epidemiological and clinical factors influenced the benefit of riluzole in the survival rates of patients with ALS.

show abstract

“…Наводе се: тежак физички рад (45,48), интензивно бављење спортом (професионални фудбалери и маратонци), пушење, траума, излагање тешким металима, олову и живи (49,50,51). Регистрована је повећана учесталост механичке трауме у болесника са ALS у поређењу са контролном групом (32,52,53,54). Описан је двоструко већи број оболелих међу ветеранима Заливског рата 1991. г.…”

Section: идиопатски (примарни) Als и обухвата: -спорадичну Als (Sals)unclassified

“…Фамилијарна ALS (FALS) која је регистрована код 6.5% наших болесника је у распону учесталости који су регистровали и други аутори у различитим градовима света од 1.5% до 7% (54,151,215,286,340).…”

Section: фамилијарна амиотрофична латерална склерозаunclassified

Prognostical factors and corelation with the survival of patients with amyotrophic lateral sclerosis

Kostić-Dedić¹

View full text Add to dashboard Cite

Хвала мојим колегама са посла, клиничког одељења неурологије Клиничко-болничког центра "Звездара" а нарочито Проф. др. Вери Цвијановић.На крају, бескрајно сам захвална својим родитељима на непрестаној подршци и инспирацији. Mедиана времена преживљавања је 3 године (95%CI 2.86-3.14). Средње време трајања болести од почетка првих симптома је 4.35 ± 0.20 година. Средње животно доба на почетку болести је 57.74 ± 11.46 година док је средње животно доба приликом постављања дијагнозе 59.21 ± 11.26 година. Булбарни почетак је регистрован код 84 (25.8%) болесника, спинални почетак код 241 (74.1%). Код болесника са спиналним почетком је средње време трајања ALS 4.5 ± 0.2 година, било значајно дуже у односу на болеснике са булбарним почетком (3.7 ± 0.4 година, p=0.016). Иако је дуже средње време трајања болести код мушкараца (4.40 ± 0.3 година) у односу на жене (4.2 ± 0.3 година), пол нема утицаја на преживљавање у нашој кохорти (p>0.05). Cox-овом поцедуром је утврђено да су: млађе животно доба на почетку болести, дуже дијагностичко кашњење, виши ALSFRS скор приликом дијагностиковања и рана примена рилузола у статистички значајној корелацији са дужим преживљавањем. ЗАКЉУЧАК: Млађе животно доба на почетку болести и дуже дијагностичко кашњење су прогностички фактори дужег преживљавања болесника са ALS који су регистровани и у студијама других аутора. Већа вредност ALSFRS скора у моменту постављања дијагнозе и рана примена рилузола су додатни прогностички фактори дужег преживљавања. Старије животно доба на почетку болести и булбарни почетак болести су фактори лошије прогнозе у нашој кохорти болесника. OBJECTIVE:In order to define the prognostic factor for survival, at the first visit, we investigated our ALS database of patients residents in Belgrade, the last 17 years. MATERIAL AND METHODS:In the period 1992.-2009. 325 patients with the diagnosis of definite or probable ALS were discovered in the Belgrade district. The survival were assessed with the Kaplan-Meier method. The prognostic value of each factor was estimated using Cox proportional hazard analyses. RESULTS:As of December 2009. 267 ALS patients (82.2%) ALS have died. The median survival time was 3 years, (95%CI: 2.86-3.14). Mean survival time from symptoms onset was 4.35 ± 0.20 years. The mean age at onset was 57.74 ± 11.46 years and the mean age at diagnosis was 59.21 ± 11.26 years. Eighty four patients (25.8%) had a bulbar onset and 241 (74.1%) had spinal onset of the disease. Mean survival time from onset for patients with spinal onset was 4.5 ± 0.2 years and 3.7 ± 0.4 years for patients with bulbar onset (p=0.016). Mean survival time for men was 4.40 ± 0.3 years and 4.2 ± 0.3 years for women (p>0.05). In the Cox multivariable model, the factors independently related to a longer survival were younger age, longer diagnostic delay, higher ALSFRS score at first examination and early riluzole treatment. CONCLUSIONS:The identification of younger age, longer diagnostic delay as predictors of prolonged survival in ALS clinic population supports the findings of several...

show abstract

Clinical and epidemiological features of motor neuron disease in south-western Greece

Cited by 45 publications

References 29 publications

Mortality rates due to amyotrophic lateral sclerosis in São Paulo City from 2002 to 2006

Mortality rates due to amyotrophic lateral sclerosis in São Paulo City from 2002 to 2006

Epidemiological and clinical factors impact on the benefit of riluzole in the survival rates of patients with ALS

Prognostical factors and corelation with the survival of patients with amyotrophic lateral sclerosis

Contact Info

Product

Resources

About